Charles Schwab Investment Management Inc. Trims Stock Holdings in INmune Bio, Inc. (NASDAQ:INMB)

Charles Schwab Investment Management Inc. decreased its position in INmune Bio, Inc. (NASDAQ:INMB) by 8.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,990 shares of the company’s stock after selling 3,285 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.15% of INmune Bio worth $183,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Financial Advocates Investment Management grew its position in shares of INmune Bio by 17.4% in the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock worth $73,000 after buying an additional 2,000 shares during the period. Rhumbline Advisers bought a new stake in INmune Bio during the second quarter worth about $121,000. Fermata Advisors LLC grew its holdings in INmune Bio by 25.2% in the third quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock worth $230,000 after purchasing an additional 8,590 shares during the period. Bank of New York Mellon Corp increased its stake in shares of INmune Bio by 124.6% during the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after purchasing an additional 32,511 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after purchasing an additional 89,091 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Scotiabank assumed coverage on INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price target on the stock. Alliance Global Partners began coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Raymond James assumed coverage on INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price target for the company.

INmune Bio Stock Down 3.3 %

Shares of NASDAQ INMB opened at $4.42 on Friday. The firm has a market cap of $98.00 million, a P/E ratio of -2.03 and a beta of 1.79. INmune Bio, Inc. has a twelve month low of $4.36 and a twelve month high of $14.74. The company has a 50 day moving average of $5.28 and a 200 day moving average of $6.55.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same period in the previous year, the firm posted ($0.48) earnings per share. As a group, equities analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO David J. Moss bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The shares were bought at an average price of $5.29 per share, for a total transaction of $52,900.00. Following the completion of the acquisition, the chief financial officer now owns 1,285,869 shares of the company’s stock, valued at $6,802,247.01. This trade represents a 0.78 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 35.20% of the stock is owned by insiders.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.